Skip to main content
Signal8
Launch Terminal

Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Eikon Therapeutics, Inc. Common Stock logo

Eikon Therapeutics, Inc. Common Stock

NASDAQ:EIKNHealthcare
-0.75%$5.31
AH$5.40+1.69%vs close
Mkt Cap$287.62M
Float31.11M
O/S54.17M
Vol
$ Vol
RVOL
Inst Own50.1%
SI20.5%
Earnings
Dilution
Eikon Therapeutics, Inc. Common Stock logoNASDAQ:EIKN$5.31-0.75%
Phase Distribution
10 lead-sponsored trials·6 active·4 completed
Phase 13
Phase 1/23
Phase 22
Phase 2/32
(1 more as collaborator)
Status Overview
Recruiting5
Active, not recruiting1
Completed4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2/3
    Recruiting

    Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

    EIK1001, Pembrolizumab (KEYTRUDA® )

    Advanced Melanoma

    Enrollment
    740
    Start
    May 2025
    Primary Completion
    Dec 2035est.
    Completion
    Dec 2040est.
    NCT06697301
  • Phase 2/3
    Recruiting

    A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

    EIK1001, Pembrolizumab (KEYTRUDA®)

    Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC

    Enrollment
    750
    Start
    Jun 2026
    Primary Completion
    Dec 2035est.
    Completion
    Dec 2040est.
    NCT07365319
  • Phase 2
    Completed

    BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

    BDB001

    Tumor, Solid

    Enrollment
    1
    Start
    Aug 2021
    Primary Completion
    Apr 2023
    Completion
    May 2023
    NCT04819373
  • Phase 2
    Active, not recruiting

    A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

    EIK1001, Pembrolizumab

    NSCLC

    Enrollment
    70
    Start
    Feb 2024
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2027est.
    NCT06246110
  • Phase 1/2
    Recruiting

    A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

    IMP1734

    Advanced Solid Tumor

    Enrollment
    156
    Start
    Dec 2023
    Primary Completion
    Jun 2027est.
    Completion
    Dec 2027est.
    NCT06253130
  • Phase 1/2
    Recruiting

    A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

    EIK1004-001 (IMP1707-001)

    Advanced Solid Tumors

    Enrollment
    130
    Start
    Apr 2025
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT06907043
  • Phase 1/2
    Recruiting

    EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

    EIK1005, pembrolizumab (KEYTRUDA® )

    Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors +5

    Enrollment
    160
    Start
    Jan 2026
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2029est.
    NCT07262619
  • Phase 1
    Completed

    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

    BDB001 (EIK1001), Pembrolizumab

    Tumor, Solid

    Enrollment
    87
    Start
    Feb 2018
    Primary Completion
    Mar 2024
    Completion
    Apr 2024
    NCT03486301
  • Phase 1
    Completed

    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

    BDB001 (EIK1001), Atezolizumab

    Tumor, Solid

    Enrollment
    40
    Start
    Nov 2019
    Primary Completion
    Jul 2024
    Completion
    Aug 2024
    NCT04196530
  • Phase 1
    Completed

    Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

    BDB018, Pembrolizumab

    Tumor, Solid

    Enrollment
    1
    Start
    Jun 2021
    Primary Completion
    Mar 2024
    Completion
    Sep 2024
    NCT04840394
Search ClinicalTrials.gov for “Eikon Therapeutics”